Research programme: hepatic glucose output inhibitors - Metabolex

Drug Profile

Research programme: hepatic glucose output inhibitors - Metabolex

Alternative Names: hepatic glucose output inhibitors research programme - Metabolex; MBX 668

Latest Information Update: 23 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Metabolex
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 23 Mar 2007 Discontinued - Preclinical for Diabetes mellitus in USA (PO)
  • 21 Aug 2003 Metabolex is screening preclinical candidates of the programme
  • 05 Jul 2001 Preclinical development for Diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top